Here we sought to overcome these common pitfalls by using homogeneous, genetically defined mutant hypomorphic conditions of the insulin signaling pathway to model diabetes type II (insulin resistance) together with a control strain [8], where all stocks have the same genetically homogenized background. This evidence concerns the gene INS and Insulin resistance.